151. Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study.
- Author
-
Teggi R, Colombo B, Gatti O, Comi G, and Bussi M
- Subjects
- Adult, Drug Combinations, Female, Follow-Up Studies, Histamine H1 Antagonists therapeutic use, Humans, Male, Migraine Disorders physiopathology, Time Factors, Treatment Outcome, Vertigo drug therapy, Vertigo physiopathology, Vestibular Diseases physiopathology, Calcium Channel Blockers therapeutic use, Cinnarizine therapeutic use, Dimenhydrinate therapeutic use, Migraine Disorders drug therapy, Vestibular Diseases drug therapy
- Abstract
Vestibular migraine (VM) is one of the most frequent causes of episodic vertigo, with a lifetime prevalence of 0.98%. Prophylactic therapy includes calcium channel blockers, beta-blockers, antiepileptic drugs and antidepressants. We studied the association of cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevertan) in a group of 22 patients affected by definite VM. Proposed therapy included one tablet twice a day for 1 month, which was repeated three times with 1 month of interval between drug intake; results were compared with those of a control group of 11 VM patients who asked to observe only lifestyle measures for migraine. The main outcome was the number of vertigo and headache crises in the 6 months before therapy and in the 6 months of follow-up. Subjects performing Arlevertan presented during the 6 months of therapy a decrease of vertigo attacks from 5.3 to 2.1 and of headaches from 4.3 to 1.7 (p < 0.0001); 68% of these subjects reported a decrease of at least 50% of vertigo attacks, while 63% of headaches. Conversely, vertigo attacks decreased from 3.5 to 2.2 and headaches from 2.6 to 2 in patients observing only lifestyle; 18% of these subjects reported a decrease of at least 50% of vertigo crises and 27% of headaches. Our data do not differ from those of previous works assessing efficacy of different prophylactic therapies for VM and reporting consistent reduction of vertigo spells in a rate of patients ranging from 60 and 80%.
- Published
- 2015
- Full Text
- View/download PDF